Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the
treatment of BPH (benign prostatic hyperplasia) versus finasteride.